Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All ClaimsSettlement Agreement and Mutual Release of All Claims • September 5th, 2008 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and The Salk Institute for Biological Studies (SALK) have entered into a Settlement Agreement and Mutual Release of All Claims (Settlement Agreement). Through the Settlement Agreement, the parties have resolved all disputes that have arisen between them including SALK’s primary claim in arbitration relating to the sale of Targretin® to Eisai Inc. in 2006. In addition, the parties have agreed to jointly seek dismissal with prejudice of all claims and counterclaims asserted in the ongoing arbitration between the parties.
